|
Tianyin Pharmaceutical (TPI) |
|
|
Unionsun Yangkuo Plaza South Renmin Rd.
Chengdu, 610041 China
phone:+86.28.8551.6696
fax:+86.28.8551.6676
|
|
| Symbol |
TPI |
| Exchange |
NYSE |
| Founded |
1994 |
| Employees |
1365 |
|
|
| www.tianyinpharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Patented biopharmaceutical, Modernized traditional Chinese medicines, Branded generics, Macrolide antibiotic API |
|
| Management |
| Guoqing Jiang, MD, Chairman & CEO; James Jiayuan Tong, MD PhD, CFO & Chief Business & Development Officer; Tao (Victor) Yang, Chief Operating Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| Pharmaceutical, China, internal medicines, gynecology, nutriceutical, otolaryngology, urology, neurology, gastroenterology, orthopedics, dermatology, pediatrics, branded generics, Azithromycin, stroke cardiovascular; inflammation, rheumatism, antiobiotic; immunity, sexual function, viral infections, H1N1 influenza |
|
|
|
| Description |
|
TPI is engaged in research, development, manufacturing, marketing and sale of patented biopharmaceutical, modernized TCMs, branded generics and other pharmaceuticals. It has three state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. |
|
| Products / Services |
TPI manufactures and markets a portfolio of 56 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. The best selling products: Ginkgo Mihuan for stroke and other cardiovascular conditions; Apu Shuangxin for inflammation and rheumatism; Azithromycin for bacterial infections; Xuelian Chongcao for immunity and sexual function; Qingre Jiedu for viral infections, H1N1 and influenza. These products totaled $10.1 million, representing 40% of most recent 2nd quarterly revenues ending 12/31/10.
|
|
| Technology / Differentiation |
| TPI employs a collaborative partnership model for its R&D which has proven cost effective, efficient and with a shorter development cycle time. It has 10 products in the product pipeline pending SFDA approval. TPI has established R&D collaboration partnerships with some of the most prestigious research and development institutions in China, including China Pharmaceutical University, Sichuan University-affiliated West China Center of Medical Sciences, and Shaanxi University of Chinese Medicines. |
|
| Market / Customers |
TPI's hospital coverage has currently expanded over 880 hospitals in China.
|
|
| Strategy |
Build its distribution and to add additional products to its portfolio both developed from the internal pipeline and provided by other manufacturers. It is also seeking to develop its international front to provide its products to the global markets.
|
|
| Funding |
| Fiscal year 2010 revenues grew 69% and Net Income by 71% from 2009. The Company is profitable and has $31 million in cash reserves as of March 1, 2011. Market Cap of $84 million. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
